Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Proton pump inhibitors (PPIs) are linked to worse survival in metastatic urothelial carcinoma patients treated with pembrolizumab. Histamine-2 receptor antagonists (H2RAs) may be a safer alternative during treatment.
Area Of Science
- Oncology
- Pharmacology
Background
- Concomitant medications can impact immune checkpoint inhibitor efficacy.
- The effect of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on pembrolizumab efficacy in metastatic urothelial carcinoma (mUC) is not well understood.
Purpose Of The Study
- To evaluate the impact of PPIs and H2RAs on oncological outcomes in mUC patients receiving pembrolizumab.
Main Methods
- Retrospective multicenter study of mUC patients treated with pembrolizumab.
- Analysis of overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), and objective response rates (ORR).
- Kaplan-Meier analysis and multivariable Cox models were used to assess outcomes.
Main Results
- Proton pump inhibitor (PPI) use was associated with significantly worse OS, CSS, and PFS.
- PPIs were a significant prognostic factor for poorer survival outcomes.
- Histamine-2 receptor antagonist (H2RA) use showed no association with survival or response rates.
Conclusions
- Proton pump inhibitors (PPIs) are associated with worse survival in mUC patients treated with pembrolizumab.
- Histamine-2 receptor antagonists (H2RAs) may serve as a viable alternative.
- Consideration of both oncological and gastrointestinal effects is crucial when managing antacid use.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...